Calcium sensitizers, a new class of inodilators

International Anesthesiology Clinics

Volumn 43, Issue 2, 2005, Pages 115-133

  Kwak, Young Lan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ACTIN; ADENOSINE A1 RECEPTOR; CALCIUM ION; CALCIUM SENSITIZER; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; INOTROPIC AGENT; LEVOSIMENDAN; MYOSIN; MYOSIN ADENOSINE TRIPHOSPHATASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PIMOBENDAN; SULMAZOLE; TROPOMYOSIN; TROPONIN C; TROPONIN I; VASODILATOR AGENT;

CALCIUM BINDING; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CALCIUM; CARDIOTONIC AGENTS; HUMANS; PHOSPHODIESTERASE INHIBITORS; VASODILATOR AGENTS;

EID: 17644414928     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aia.0000157496.19118.b1     Document Type: Review

References (91)

1. ++ as an inotropic mechanism. Circulation. 1986;73:III-85-III98.
2. Farah AE, Alousi AA, Schwarz RP Jr. Positive inotropic agents. Annu Rev Pharmacol Toxicol. 1984;24:275-328.
3. 2+ sensitization as mechanisms of action of physiological interventions and inotropic agents in intact myocardial cells. Jpn Heart J. 1998;39:1-44.
4. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol. 2002;40:323-338.
5. 2+ sensitive force, stiffness and unloaded shortening velocity (Vmax) in isolated contractile structures from mammalian heart muscle. Arzneimittelforschung Drug Res. 1981;31:188-191.
6. Bristol JA, Sircar I, Moos WH, et al. Cardiotonic agents. L4,5-Dihydro-6[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J Med Chem. 1984;27:1099-1101.
7. Nielsen-Kudsk JE, Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure? J Cardiovasc Pharmacol. 1995;26:S77-S84.
8. Haikala H, Linden I-B. Mechanism of action of calcium sensitizing drugs. J Cardiovasc Pharmacol. 1995;26:S10-S19.
9. Solaro RJ, Gambassi G, Warshaw DM, et al. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circ Res. 1993;73:981-990.
10. Holubarsch C. New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Cardiology. 1997;88:12-20.
11. Duncker DJ, Verdouw PD. Inotropic therapy of heart failure. Scand Cardiovasc J. 2002; 36:131-135.
12. Sata M, Sugiura S, Yamashita H, et al. Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin. Eur J Pharmacol. 1995;290:55-59.
13. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res. 1995;77:107-113.
14. + channel in rat ventricular cells. J Pharmacol Exp Ther. 1997; 283:375-383.
15. 2+ activation of skinned human myocardium. Eur J Pharmacol. 1989;165:305-308.
16. Kitada Y, Narimatsu A, Matsumura N, et al. Contractile proteins: possible targets for the cardiotonic action of MCI-154, a novel cardiotonic agent? Eur J Pharmacol. 1987;134: 229-231.
17. Lues I, Beier N, Jonas R, et al. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers. J Cardiovasc Pharmacol. 1993;21:883-892.
18. Varro A, Papp JG. Classification of positive inotropic actions based on electrophysiologic characteristics: where should calcium sensitizers be placed? J Cardiovasc Pharmacol. 1995;26:S32-S44.
19. Harrison SM, Bers DM. Influence of temperature on the calcium sensitivity of the myofilaments of skinned ventricular muscle from the rabbit. J Gen Physiol. 1989;93:411-428.
20. Tsutsui H, Kinugawa S, Ide T, et al. Positive inotropic effects of calcium sensitizers on normal and failing cardiac myocytes. J Cardiovasc Phamacol. 2001;37:16-24.
21. Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol. 1995;25:794-801.
22. Haikala H, Levijoki J, Linden I-B. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol. 1995;27:2155-2165.
23. Bristow MR, Shakar SF, Linseman JV, et al. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail 2001;7:8-12.
24. Tobias AH, Slinker BK, Kirkpatrick RD, et al. Functional effects of EMD-57033 in isovolumically beating isolated rabbit hearts. Am J Physiol. 1996;271:H51-H58.
25. Gambassi G, Capogrossi MC, Klockow M, et al. Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes. Am J Physiol. 1993;264: H728-H738.
26. 2+ sensitization with a new cardiotonic agent, MCI-154, on diseased human hearts. Cardiovasc Res. 1995;30: 915-922.
27. Takahashi R, Talukder MAH, Endoh M. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium. Eur J Pharmacol. 2000; 400:103-112.
28. Haikala H, Kaheinen P, Levijoki J, et al. The role of cAMP and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res. 1997;34:536-546.
29. Jamali IN, Kersten JR, Pagel PS, et al. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg. 1997;85:23-29.
30. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522-531.
31. McBride BF, White CM. Levosimendan: implications for clinicians. J Clin Pharmacol. 2003;43:1071-1081.
32. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003;107:81-86.
33. Rapundalo ST, Solaro RJ, Kranias EG. Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ Res. 1989;64:104-111.
34. Cleland JGF, McGowan J. Levosimendan: a new era for inodilator therapy for heart failure? Curr Opin Cardiol. 2002;17:257-265.
35. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999;288:316-325.
36. Toivonen L, Viitasalo M, Sundberg S, et al. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol. 2000;35:664-669.
37. Lilleberg J, Ylönen V, Lehtonen L, et al. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J. 2004;38:80-84.
38. Sandell EP, Hayha M, Antila S, et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol. 1995;26: S57-S62.
39. Antila S, Jarvinen A, Honkanen T, et al. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitizer levosimendan and warfarin. Eur J Clin Pharmacol. 2000;56:705-710.
40. Sundberg S, Antila S, Scheinin H, et al. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther. 1998;36:629-635.
41. Jonsson EN, Antila S, McFadyen L, et al. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol. 2003;55: 544-551.
42. Antila S, Huuskonen H, Nevalainen T, et al. Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharmacol Sci. 1999;9:85-91.
43. Kivikko M, Antila S, Eha J, et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during and extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002;42:43-51.
44. Kaheinen P, Pollesello P, Levijoki J, et al. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol. 2004;43: 555-561.
45. Tassani P, Schad H, Heimisch W, et al. Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc Drug Ther. 2002;16:435-441.
46. Janssen PML, Datz N, Zeitz O, et al. Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol. 2000;404:191-199.
47. Udvary E, Papp JG, Vegh A. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction. Br J Pharmacol. 1995;114:656-661.
48. Follath F, Cleland JGF, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
49. Thackray S, Eastaugh J, Freemantle N, et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: a meta-regression analysis. Eur J Heart Fail. 2002;4:515-529.
50. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure: Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet. 1997;349:971-977.
51. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med. 1991; 325:1468-1475.
52. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation. 2000;102:2222-2227.
53. Moiseyev VS, Pōder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: A randomized, placebo-controlled, double-blind study (RUSSIAN). Eur Heart J. 2002;23:1422-1432.
54. Pōder P, Eha J, Antila S, et al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drug Ther. 2003;17:451-458.
55. ATP channels. Anesth Analg. 2000;90:5-11.
56. Krassói I, Pataricza J, Kun A, et al. Calcium-dependent vasorelaxant capacity of levosimendan in porcine and human epicardial coronary artery preparations. Cardiovasc Drug Ther. 2000;14:691-693.
57. Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177-2182.
58. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J. 1998;19:660-668.
59. Nijhawan N, Nicolosi AC, Montgomery MW, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999;34:219-228.
60. Lehmann A, Lang J, Boldt J, et al. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit. 2002;10:MT89-MT93.
61. Oldner A, Konrad D, Weitzberg E, et al. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med. 2001;29:2185-2193.
62. De Witt BJ, Ibrahim IN, Bayer E, et al. An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg. 2002;94:1427-1433.
63. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anesthetized dogs. Br J Pharmacol 1996;119:609-615.
64. Vegh A, Papp JG, Udvary E, et al. Haemodynamic effects of calcium sensitizing agents. J Cardiovasc Pharmacol. 1995;26:S20-S31.
65. The Pimobendan in Congestive Heart Failure Investigators (PICO). Effect of pimobendan on exercise capacity in patients with heart failure: main results from the pimobendan in congestive heart failure (PICO) trial. Heart. 1996;76:223-231.
66. Shiga T, Wakaumi M, Yajima T, et al. β-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases. Cardiovasc Drug Ther. 2002;16: 259-263.
67. The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure-the effects of pimobendan on chronic heart failure study (EPOCH study). Circ J. 2002;66:149-157.
68. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Circulation. 1992;85:942-949.
69. Katz SD, Kubo SH, Jessup M, et al. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure. Am Heart J. 1992;123:95-103.
70. Ishiki R, Ishihara H, Izawa H, et al. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure. J Cardiovasc Pharmacol. 2000;35:897-905.
71. Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol. 1999;33:1400-1407.
72. Matsumori A, Nunokawa Y, Sasayama S. Pimobendan inhibits the activation of transcription factor NF-κB A mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase. Life Sci. 2000;67:2513-2519.
73. Yoshikawa T, Baba A, Suzuki M, et al. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. Am J Cardiol. 2000;85:1495-1497.
74. Watanabe E, Shiga T, Matsuda N, et al. Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension. Cardiovasc Drug Ther. 2003;17:375-379.
75. 2+ sensitivity of reconstituted thin filament; a study using a novel in vitro motility assay technique. Circ Res. 1995;76: 626-633.
76. Abe Y, Sekioka K, Ishisu R, et al. Restoration of ischemic contractile failure of indo-1-loaded guinea pig heart by a calcium sensitizer, MCI-154. J Pharmacol Exp Ther. 1996; 279:47-55.
77. 2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor. Am Heart J. 1997;133:283-289.
78. Mori M, Takeuchi M, Takaoka H, et al. Oxygen-saving effect of a new cardiotonic agent, MCI-154, in diseased human hearts. J Am Coll Cardiol. 1997;29:613-622.
79. Abe Y, Kitada Y, Narimatsu A. Beneficial effect of MCI-154, a cardiotonic agent, on ischemic contractile failure and myocardial acidosis of dog hearts: comparison with dobutamine, milrinone and pimobendan. J Pharmacol Exp Ther. 1992;261:1087-1095.
80. Takahashi S, Cho S, Hara T, et al. The interaction of MCI-154, a calcium sensitizer, and isoflurane on systemic and coronary hemodynamics in chronically instrumented dogs. Anesth Analg. 2004;98:30-36.
81. Teramura S, Yamakado T, Maeda M, et al. Effects of MCI-154, a calcium sensitizer, on left ventricular systolic and diastolic function in pacing-induced heart failure in the dog. Circulation. 1997;95:732-739.
82. + channel of vascular smooth muscle cells. Life Sci. 1995;56:PL291-PL298.
83. 2+-sensitizer" MCI-154 in intact pigs. Scand Cardiovasc J. 2002;36:172-179.
84. Grandis DJ, DelNido PJ, Koretsky AP. Functional and energetic effects of the inotropic agents EMD-57033 and BAPTA on the isolated rat heart. Am J Physiol. 1995;269:C472-C479.
85. Popping S, Mruck S, Fischer Y, et al. Economy of contraction of cardiomyocytes as influenced by different positive inotropic interventions. Am J Physiol. 1996;271:H357-H364.
86. Lee JA, Shah N, White J, et al. A novel thiadiazinone derivative fully reverses acidosis-induced depression of force in cardiac muscle by a calcium-sensitizing effect. Clin Sci. 1993;84:141-144.
87. Haeusler G, Jonas R, Minck KO, et al. In vivo evidence of positive inotropism of EMD 57033 through calcium sensitization. J Cardiovasc Pharmacol. 1997;29:647-655.
88. ++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther. 1997;280:247-254.
89. Remme WJ. Inodilator therapy for heart failure. Circulation. 1993;87:IV97-IV107.
90. Lee JA, Allen DG. EMD 53998 sensitizes the contractile proteins to calcium in intact ferret ventricular muscle. Circ Res. 1991;69:927-936.
91. 2+ sensitivity in diabetic rat myocardium: potential usefulness as inotropic agents. J Pharmacol Exp Ther. 2001;298:613-622.